431 related articles for article (PubMed ID: 19934815)
1. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
[TBL] [Abstract][Full Text] [Related]
2. We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office.
Shah GY; Ambatipudi S; Fernandes M; Lakshmipathy M; Varma PV; Sachdeva V; Pathengay A
Retina; 2010 Sep; 30(8):1325-6; author reply 1326-7. PubMed ID: 20827150
[No Abstract] [Full Text] [Related]
3. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
[TBL] [Abstract][Full Text] [Related]
4. The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
El-Ashry MF; Dhillon B
Retina; 2009 May; 29(5):720-1; author reply 721-2. PubMed ID: 19430287
[No Abstract] [Full Text] [Related]
5. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.
Mason JO; White MF; Feist RM; Thomley ML; Albert MA; Persaud TO; Yunker JJ; Vail RS
Retina; 2008 Apr; 28(4):564-7. PubMed ID: 18398358
[TBL] [Abstract][Full Text] [Related]
6. Bilateral intravitreal injection of antivascular endothelial growth factor therapy.
Mahajan VB; Elkins KA; Russell SR; Boldt HC; Gehrs KM; Weingeist TA; Stone EM; Abràmoff MD; Liu D; Folk JC
Retina; 2011 Jan; 31(1):31-5. PubMed ID: 21187731
[TBL] [Abstract][Full Text] [Related]
7. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
8. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
10. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients.
Matthews JL; Dubovy SR; Goldberg RA; Flynn HW
Ophthalmology; 2014 Mar; 121(3):702-8. PubMed ID: 24439760
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.
Mezad-Koursh D; Goldstein M; Heilwail G; Zayit-Soudry S; Loewenstein A; Barak A
Retina; 2010; 30(7):1051-7. PubMed ID: 20616683
[TBL] [Abstract][Full Text] [Related]
12. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.
Chan CK; Abraham P; Meyer CH; Kokame GT; Kaiser PK; Rauser ME; Gross JG; Nuthi AS; Lin SG; Daher NS
Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998
[TBL] [Abstract][Full Text] [Related]
13. Severe intraocular inflammation after intravitreal injection of bevacizumab.
Sato T; Emi K; Ikeda T; Bando H; Sato S; Morita S; Oyagi T; Sawada K
Ophthalmology; 2010 Mar; 117(3):512-6, 516.e1-2. PubMed ID: 20031229
[TBL] [Abstract][Full Text] [Related]
14. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC
Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
[TBL] [Abstract][Full Text] [Related]
15. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection.
Chong DY; Anand R; Williams PD; Qureshi JA; Callanan DG
Retina; 2010 Oct; 30(9):1432-40. PubMed ID: 20559156
[TBL] [Abstract][Full Text] [Related]
16. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
18. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.
Yamashiro K; Tsujikawa A; Miyamoto K; Oh H; Otani A; Tamuara H; Ooto S; Sasahara M; Iwama D; Yoshimura N
Retina; 2010 Mar; 30(3):485-90. PubMed ID: 19952993
[TBL] [Abstract][Full Text] [Related]
19. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA
Retina; 2013; 33(7):1407-16. PubMed ID: 23492945
[TBL] [Abstract][Full Text] [Related]
20. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
Wickremasinghe SS; Michalova K; Gilhotra J; Guymer RH; Harper CA; Wong TY; Qureshi S
Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
